Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomised, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose (Part A) and Multiple Ascending Dose (Part B) Study to Assess the Safety, Tolerability and Pharmacokinetics of IV Infusion of TESP-0401 in Healthy Participants

NCT07658638 is registered in ClinicalTrials.gov with Tes Pharma S.r.l. as lead sponsor.

NCT NCT07658638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07658638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomised, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose (Part A) and Multiple Ascending Dose (Part B) Study to Assess the Safety, Tolerability and Pharmacokinetics of IV Infusion of TESP-0401 in Healthy Participants
Lead sponsor
Tes Pharma S.r.l.
Phase
Phase 1
Overall status
Recruiting
Start date
July 8, 2026
Completion date
March 3, 2027
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers